Working With Us

CHAIN aims to build value for our stakeholders while delivering positive societal impacts in a sustainable, ethical and principled manner. We do this by demonstrating technology excellence and leadership, and by working closely with partners to build trust and confidence.

CHAIN has a proven track record for delivery, operates globally and sits at the interface between academia and industry. In addition, we have a track record obtaining UK and EU grant awards to support research costs for both academic and industry partners for strategic development projects.

Development and Commercial Partners

CHAIN seeks partners from the healthcare and pharmaceutical industries that can benefit from the Company’s unique delivery platform, using anaerobic Clostridia bacteria. In addition, CHAIN seeks collaborative partners for the development of novel peptides and therapeutic molecules for gut diseases such as Inflammatory Bowel Disease, Crohn’s Disease and Ulcerative Colitis. CHAIN’s platform is supported by a large microbial culture collection, modular plasmid vectors, and world-leading synthetic biology expertise.


Building a team of experts:

At CHAIN, we are building a team of expert scientists and business specialists to develop the company into a global healthcare leader specialising in diseases related to the human microbiome. We value hard work and creativity, and seek talented individuals who share our founder’s vision.

Besides any specific current opportunities listed below, we are keen to hear from exceptional candidates across a number of focus areas: the human microbiome, immunology, synthetic biology, and regulatory affairs. Expertise within a clinical setting, working with anaerobes, and taking therapeutics to market is desirable. In addition we are interested in experts who can help shape and manage the drug development process in our business operations.

CHAIN is committed to promoting equal opportunities in employment. The company offers a competitive compensation and benefits package. If you are interested in working for CHAIN please contact info @

Current opportunities:

Fermentation Scientist

We are currently looking for a highly motivated fermentation scientist with experience in bacterial fermentation process development at our base in the University of Nottingham. The ideal candidate will have experience working with Clostridia and/or spore production, preferable in an industrial environment. Besides working closely with the strain development and analytical team, the successful applicant is expected to liaise with external collaborators and contractors. The post holder will be responsible for strain characterisation, fermentation process development and scale-up, including data collection, interpretation and presentation of results.

We are looking for an innovative individual with a track record in fermentation process development and a strong desire to succeed. The ideal candidate will be a team player but also able to work independently and implement a milestone driven development plan. The candidate should have excellent interpersonal and communication skills together with accuracy, close attention to detail and good time management.

The candidate should have:

  • A degree in Microbiology, Biochemistry, Biotechnology or a related Biological Science
  • A Ph.D. or M.Sc. with >2 years of relevant experience in fermentation
  • Experience handling anaerobic microorganisms preferably Clostridia

CHAIN offers a competitive salary commensurate with age and experience. The closing date for applications is 31st of July 2017.

Please send your CV and application letter to info @

PhD Studentships:

Title: Understanding the role of microbial metabolites in the initiation and progression of Crohn’s Disease (CD)

Location: University of Nottingham, School of Medicine

Supervisors: Dr Nicholas Hannan (UoN); Dr Daniela Heeg (CHAIN)

Summary: This project will bring together two advanced technologies developed by Hannan (in-vitro IBD models) and CHAIN Biotechnology (engineering of bacteria to deliver bio-therapeutic products). During the project we will create an in-vitro model of CD using primary tissue biopsy from patients with CD. In collaboration with CHAIN Biotechnology we will then investigate how bacterial metabolites influence gene expression in CD and healthy intestinal epithelium and determine the feasibility of using engineered bacteria as a microbial vehicle for delivering bioactives to the gut to treat CD.

Apply here

CHAIN is currently looking to expand further into clinical and healthcare research related to the gut microbiome. Advertisements for experienced positions in clinical research and regulatory affairs will be displayed here shortly.

Please follow us here, on twitter, and on LinkedIn for future job advertisements.